Neuropsychological and neuropsychiatric aspects of Huntington's disease
暂无分享，去创建一个
[1] Jane S. Paulsen,et al. A test of odor fluency in patients with Alzheimer's and Huntington's disease. , 1999, Journal of clinical and experimental neuropsychology.
[2] G. Pearlson,et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. , 1996, Archives of neurology.
[3] M. Hayden,et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease , 1993, Nature Genetics.
[4] L. Bäckman,et al. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. , 1997, Brain : a journal of neurology.
[5] I. Shoulson,et al. A prospective evaluation of cognitive decline in early Huntington's disease , 1995, Neurology.
[6] R N Gunn,et al. Huntington's disease progression. PET and clinical observations. , 1999, Brain : a journal of neurology.
[7] P Boesiger,et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. , 1996, Brain : a journal of neurology.
[8] I. Shoulson,et al. Clinical‐pathologic correlation in Huntington's disease , 1989, Neurology.
[9] M. Albert,et al. The `subcortical dementia' of progressive supranuclear palsy , 1974, Journal of neurology, neurosurgery, and psychiatry.
[10] J. Brandt,et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at‐risk persons , 1994, Neurology.